Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design

Abbas Ali Qayyum; Mandana Haack-Sørensen; Anders Bruun Mathiasen; Erik Jørgensen; Annette Ekblond; Jens Kastrup

doi:10.2217/rme.12.17

Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design

Abbas Ali Qayyum, Mandana Haack-Sørensen, Anders Bruun Mathiasen, Erik Jørgensen, Annette Ekblond, Jens Kastrup

99 Citationer (Scopus)

Abstract

Adipose tissue represents an abundant, accessible source of multipotent adipose-derived stromal cells (ADSCs). Animal studies have suggested that ADSCs have the potential to differentiate in vivo into endothelial cells and cardiomyocytes. This makes ADSCs a promising new cell source for regenerative therapy to replace injured tissue by creating new blood vessels and cardiomyocytes in patients with chronic ischemic heart disease. The aim of this special report is to review the present preclinical data leading to clinical stem cell therapy using ADSCs in patients with ischemic heart disease. In addition, we give an introduction to the first-in-man clinical trial, MyStromalCell Trial, which is a prospective, randomized, double-blind, placebo-controlled study using culture-expanded ADSCs obtained from adipose-derived cells from abdominal adipose tissue and stimulated with VEGF-A(165) the week before treatment.

Originalsprog	Engelsk
Tidsskrift	Regenerative Medicine
Vol/bind	7
Udgave nummer	3
Sider (fra-til)	421-8
Antal sider	8
ISSN	1746-0751
DOI	https://doi.org/10.2217/rme.12.17
Status	Udgivet - 2012

Adgang til dokumentet

10.2217/rme.12.17

Citationsformater

@article{f9f412b3cc724c55bda214bc361c8053,

title = "Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design",

abstract = "Adipose tissue represents an abundant, accessible source of multipotent adipose-derived stromal cells (ADSCs). Animal studies have suggested that ADSCs have the potential to differentiate in vivo into endothelial cells and cardiomyocytes. This makes ADSCs a promising new cell source for regenerative therapy to replace injured tissue by creating new blood vessels and cardiomyocytes in patients with chronic ischemic heart disease. The aim of this special report is to review the present preclinical data leading to clinical stem cell therapy using ADSCs in patients with ischemic heart disease. In addition, we give an introduction to the first-in-man clinical trial, MyStromalCell Trial, which is a prospective, randomized, double-blind, placebo-controlled study using culture-expanded ADSCs obtained from adipose-derived cells from abdominal adipose tissue and stimulated with VEGF-A(165) the week before treatment.",

keywords = "Adipose Tissue, Animals, Chronic Disease, Clinical Trials as Topic, Humans, Mesenchymal Stem Cell Transplantation, Mesenchymal Stromal Cells, Myocardial Ischemia, Research Design",

author = "Qayyum, {Abbas Ali} and Mandana Haack-S{\o}rensen and Mathiasen, {Anders Bruun} and Erik J{\o}rgensen and Annette Ekblond and Jens Kastrup",

year = "2012",

doi = "10.2217/rme.12.17",

language = "English",

volume = "7",

pages = "421--8",

journal = "Regenerative Medicine",

issn = "1746-0751",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

TY - JOUR

T1 - Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial)

T2 - study design

AU - Qayyum, Abbas Ali

AU - Haack-Sørensen, Mandana

AU - Mathiasen, Anders Bruun

AU - Jørgensen, Erik

AU - Ekblond, Annette

AU - Kastrup, Jens

PY - 2012

Y1 - 2012

N2 - Adipose tissue represents an abundant, accessible source of multipotent adipose-derived stromal cells (ADSCs). Animal studies have suggested that ADSCs have the potential to differentiate in vivo into endothelial cells and cardiomyocytes. This makes ADSCs a promising new cell source for regenerative therapy to replace injured tissue by creating new blood vessels and cardiomyocytes in patients with chronic ischemic heart disease. The aim of this special report is to review the present preclinical data leading to clinical stem cell therapy using ADSCs in patients with ischemic heart disease. In addition, we give an introduction to the first-in-man clinical trial, MyStromalCell Trial, which is a prospective, randomized, double-blind, placebo-controlled study using culture-expanded ADSCs obtained from adipose-derived cells from abdominal adipose tissue and stimulated with VEGF-A(165) the week before treatment.

AB - Adipose tissue represents an abundant, accessible source of multipotent adipose-derived stromal cells (ADSCs). Animal studies have suggested that ADSCs have the potential to differentiate in vivo into endothelial cells and cardiomyocytes. This makes ADSCs a promising new cell source for regenerative therapy to replace injured tissue by creating new blood vessels and cardiomyocytes in patients with chronic ischemic heart disease. The aim of this special report is to review the present preclinical data leading to clinical stem cell therapy using ADSCs in patients with ischemic heart disease. In addition, we give an introduction to the first-in-man clinical trial, MyStromalCell Trial, which is a prospective, randomized, double-blind, placebo-controlled study using culture-expanded ADSCs obtained from adipose-derived cells from abdominal adipose tissue and stimulated with VEGF-A(165) the week before treatment.

KW - Adipose Tissue

KW - Animals

KW - Chronic Disease

KW - Clinical Trials as Topic

KW - Humans

KW - Mesenchymal Stem Cell Transplantation

KW - Mesenchymal Stromal Cells

KW - Myocardial Ischemia

KW - Research Design

U2 - 10.2217/rme.12.17

DO - 10.2217/rme.12.17

M3 - Journal article

C2 - 22594332

SN - 1746-0751

VL - 7

SP - 421

EP - 428

JO - Regenerative Medicine

JF - Regenerative Medicine

IS - 3

ER -

Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater